Gradient Investments LLC Decreases Holdings in Boston Scientific Corporation $BSX

Key Points

• Gradient Investments LLC has reduced its stake in Boston Scientific by 2.7%, now holding $23.46 million worth of shares after selling 5,961 shares in the second quarter.
• Boston Scientific reported quarterly earnings of $0.75 per share, exceeding analysts' expectations, and its revenue increased by 22.8% year-over-year, reaching $5.06 billion.
• Analysts have revised their price targets for Boston Scientific, with UBS raising its target from $130 to $135 and Robert W. Baird increasing it from $117 to $123, indicating a generally positive sentiment toward the stock.

Gradient Investments LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,414 shares of the medical equipment provider's stock after selling 5,961 shares during the period. Gradient Investments LLC's holdings in Boston Scientific were worth $23,460,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. E. Ohman J or Asset Management AB boosted its stake in Boston Scientific by 11.5% during the 2nd quarter. E. Ohman J or Asset Management AB now owns 414,316 shares of the medical equipment provider's stock valued at $44,502,000 after purchasing an additional 42,616 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Boston Scientific by 5.9% during the second quarter. Parallel Advisors LLC now owns 16,370 shares of the medical equipment provider's stock worth $1,758,000 after acquiring an additional 911 shares in the last quarter. Wesbanco Bank Inc. bought a new position in shares of Boston Scientific in the second quarter worth $1,545,000. Peak Financial Advisors LLC bought a new position in shares of Boston Scientific in the second quarter worth $489,000. Finally, Thurston Springer Miller Herd & Titak Inc. increased its holdings in shares of Boston Scientific by 21.0% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 25,289 shares of the medical equipment provider's stock worth $2,716,000 after purchasing an additional 4,394 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Down 0.5%

BSX stock traded down $0.46 during mid-day trading on Wednesday, reaching $98.52. The company had a trading volume of 12,060,694 shares, compared to its average volume of 7,617,995. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $145.98 billion, a PE ratio of 58.64, a price-to-earnings-growth ratio of 2.40 and a beta of 0.65. The firm has a 50 day moving average of $104.71 and a 200 day moving average of $102.22. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm earned $0.62 EPS. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last quarter. Insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BSX. Citigroup reissued a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. UBS Group raised their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Truist Financial lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and an average target price of $118.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.